研究業績
国際学会発表 2023年度
- Umegaki S，Shirota H，Iwasaki T，Kasahara Y，Ishioka C．Differential role of CD8 cells and CD4 cells in anti-tumor immunity triggered by tumor cell apoptosis using HSVtk/GCV system．AACR Annual Meeting 2023．Orland, USA．Poster April 19(2023)
- Okuma H S，Yonemori K，Ishioka C，Baba E，Kinoshita I，Muto M，Imasa M S B，Voon P J，Almeida K Y d，Hoo H F S，Ichimura M，Mizoguchi C，Munakata W，Kohsaka S，Shibata T，Yatabe Y，Nakamura K，Mano H，Yamamoto N．An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects．2023 ASCO Annual Meeting In-Person(Chicago, USA) & Online．Publication only June 2-6(2023)
- Tahara M，Shimoi T，Nishiwaki S，Tanaka S，Baba E，Muto M，Kinoshita I，Sakai D，Tabata M，Hayashi H，Ishioka C，Mamesaya N，Yamamoto N．Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901)．2023 ASCO Annual Meeting．In-Person(Chicago, USA) & Online．Poster June 3(2023)
- .Ouchi K．The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer．ESMO Asia Congress 2023．Singapore．Poster Dec 12(2023)
- Ouchi K，Tsuji A，Shiozawa M，Kawai T，Yasui H，Ota H，Kochi M，Manaka D，Ohori H，Miyake T，Yamaguchi T，Matsuura M，Sagawa T，Makiyama A，Wakamura K，Takeuchi M，Ichikawa W，Fujii M，Ishioka C，Sunakawa Y．Genome-wide DNA methylation status predicts the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: a biomarker study of the DEEPER trial (JACCRO CC-13AR)．ASCO GI 2024 Gastrointestinal Cancers Symposium．Singapore．Poster Jan 20（2024）